Literature DB >> 22570362

Outcomes of children following a first hospitalization for dilated cardiomyopathy.

Seth A Hollander1, Daniel Bernstein, Justin Yeh, Duy Dao, Heather Y Sun, David Rosenthal.   

Abstract

BACKGROUND: We hypothesized that children with dilated cardiomyopathy who require hospital admission are at increased risk for death or transplantation during their first hospitalization and in the first year that follows. We also assessed the value of routine data collected during that time to predict death or the need for transplantation prior to discharge and within 1 year of admission. METHODS AND
RESULTS: We conducted a retrospective review of 83 pediatric patients with dilated cardiomyopathy whose initial hospitalization fell between 2004 and 2009. The mean age at hospitalization was 7 years. The majority of patients demonstrated moderate or severe left ventricular dysfunction on initial echocardiogram (80%) and/or the need for intravenous inotropes within 7 days of hospital admission (69%). Five patients (6%) died, and 15 (18%) were transplanted in the initial hospitalization. At 1 year, 11/71 (15%) had died, and 27/71 (38%) were transplanted. The overall freedom from death, transplantation, or rehospitalization at 1 year following admission was 21%. Fractional shortening, left ventricular ejection fraction, serum cholesterol, uric acid, mixed venous saturation, and atrial filling pressures were all predictive of death or transplantation during the initial hospitalization. Left ventricular ejection fraction was predictive of death or transplantation at 1 year.
CONCLUSIONS: The first hospitalization for dilated cardiomyopathy marks a period of high risk for clinical decline, end stage heart failure, and the need for cardiac transplantation. Echocardiographic function and hemodynamic and serum measurements may aid in predicting outcomes. Despite medical management, most patients will be rehospitalized and/or require cardiac transplantation within 1 year of admission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22570362     DOI: 10.1161/CIRCHEARTFAILURE.111.964510

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  11 in total

1.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

2.  Dilated cardiomyopathy in a national paediatric population.

Authors:  Muhammad Bassem Jammal Addin; David Young; Sarah McCarrison; Lindsey Hunter
Journal:  Eur J Pediatr       Date:  2019-06-11       Impact factor: 3.183

3.  Neutrophil-to-lymphocyte ratio used as prognostic factor marker for dilated cardiomyopathy in childhood and adolescence.

Authors:  Fátima Derlene da Rocha Araújo; Rose Mary Ferreira da Lisboa Silva; Camilla Andrade Lima Oliveira; Zilda Maria Alves Meira
Journal:  Ann Pediatr Cardiol       Date:  2019 Jan-Apr

4.  Dysregulation of cardiolipin biosynthesis in pediatric heart failure.

Authors:  Kathryn C Chatfield; Genevieve C Sparagna; Carmen C Sucharov; Shelley D Miyamoto; Jonathan E Grudis; Rebecca D Sobus; Jamie Hijmans; Brian L Stauffer
Journal:  J Mol Cell Cardiol       Date:  2014-06-14       Impact factor: 5.000

5.  Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children.

Authors:  Javier J Lasa; Michael Gaies; Lauren Bush; Wenying Zhang; Mousumi Banerjee; Jeffrey A Alten; Ryan J Butts; Antonio G Cabrera; Paul A Checchia; Justin Elhoff; Angela Lorts; Joseph W Rossano; Kurt Schumacher; Lara S Shekerdemian; Jack F Price
Journal:  Circ Heart Fail       Date:  2020-04-17       Impact factor: 8.790

6.  Plasma exchange for the patients with dilated cardiomyopathy in children is safe and effective in improving both cardiac function and daily activities.

Authors:  Takeshi Moriguchi; Keiichi Koizumi; Kenichi Matsuda; Norikazu Harii; Junko Goto; Daiki Harada; Hisanori Sugawara; Minako Hoshiai; Hiroaki Kise; Akiyasu Baba
Journal:  J Artif Organs       Date:  2017-04-05       Impact factor: 1.731

7.  Evaluation of the diagnostic work-up in children with myocarditis and idiopathic dilated cardiomyopathy.

Authors:  S L den Boer; R P J Meijer; G G van Iperen; A D J Ten Harkel; G J du Marchie Sarvaas; B Straver; L A J Rammeloo; R B Tanke; J J A van Kampen; M Dalinghaus
Journal:  Pediatr Cardiol       Date:  2014-09-07       Impact factor: 1.655

8.  Predictors of disease progression in pediatric dilated cardiomyopathy.

Authors:  Kimberly M Molina; Peter Shrader; Steven D Colan; Seema Mital; Renee Margossian; Lynn A Sleeper; Girish Shirali; Piers Barker; Charles E Canter; Karen Altmann; Elizabeth Radojewski; Elif Seda Selamet Tierney; Jack Rychik; Lloyd Y Tani
Journal:  Circ Heart Fail       Date:  2013-10-16       Impact factor: 8.790

Review 9.  Clinical cardiac regenerative studies in children.

Authors:  Imre J Pavo; Ina Michel-Behnke
Journal:  World J Cardiol       Date:  2017-02-26

10.  Increased myocyte calcium sensitivity in end-stage pediatric dilated cardiomyopathy.

Authors:  Stephanie J Nakano; John S Walker; Lori A Walker; Xiaotao Li; Yanmei Du; Shelley D Miyamoto; Carmen C Sucharov; Anastacia M Garcia; Max B Mitchell; Amrut V Ambardekar; Brian L Stauffer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-10-18       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.